Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

• Revenue in EUR (TTM)60.80m
• Net income in EUR63.90m
• Incorporated2012
• Employees239.00

• Location
  Formycon AGFraunhoferstrasse 15MARTINSRIED 82152GermanyDEU
• Phone+49 89 864667100
• Fax+49 89 864667110
• Websitehttps://www.formycon.com/